Viewing Study NCT01905592

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:35 PM
Ignite Modification Date: 2026-02-22 @ 4:53 PM
Study NCT ID: NCT01905592
Status: TERMINATED
Last Update Posted: 2022-11-15
First Post: 2013-07-18
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Sponsor: Tesaro, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Neoplasms, Breast View
None Carcinoma of Breast View
None Human Epidermal Growth Factor 2 Negative Carcinoma of Breast View
None BRCA1 Gene Mutation View
None BRCA2 Gene Mutation View
None Ovarian Neoplasms View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Human Epidermal Growth Factor 2 Negative Carcinoma of Breast View
None BRCA1 Gene Mutation View
None BRCA2 Gene Mutation View
None PARP Inhibitor View
None BRCA View